Pfizer Inc. (NYSE:PFE) Shares Acquired by Douglass Winthrop Advisors LLC

Douglass Winthrop Advisors LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 78.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 85,776 shares of the biopharmaceutical company’s stock after purchasing an additional 37,653 shares during the quarter. Douglass Winthrop Advisors LLC’s holdings in Pfizer were worth $2,276,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter worth $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the 4th quarter worth $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the 4th quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the 4th quarter valued at about $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Shares of Pfizer stock opened at $26.17 on Friday. The firm has a market cap of $148.29 billion, a PE ratio of 18.56, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $26.18 and a 200 day moving average price of $27.07.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the business earned $0.10 earnings per share. The business’s revenue was up 24.7% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

PFE has been the subject of several research analyst reports. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.